BENG0003 Chap.3 Ethics and Regulation of Biotherapeutics
Ethics and Regulation of Biotherapeutics
Ethics and Regulation of Biotherapeutics covers the Week 8 material on how a new therapy reaches patients legally and responsibly.
It follows the FDA route from pre-clinical animal studies through the Investigational New Drug application and its 30-day wait, then Phase I safety testing in 20 to 80 healthy volunteers, Phase II efficacy testing in 100 to 300 patients and double-blind Phase III comparisons in 1,000 to 3,000 patients, ending in a New Drug Application or a Biologics License Application.
It corrects two easy overstatements about exceptions for counter-terrorism products and orphan drugs. The chapter then explains Good Manufacturing Practice, the split between quality control, quality assurance and validation, and what a standard operating procedure must contain.
It classifies advanced therapy medicinal products into gene therapies, somatic cell therapies, tissue-engineered products and combined products, and applies the EU default rules to lecture-style cases.
Finally it turns to professional ethics: the shared engineering principles adopted by IChemE, historical vaccine ethics, the consent and licensing rules around human embryonic stem cells, a qualified view of induced pluripotent stem cells, and animal research law.
What this chapter covers
- 01
Why medicines are regulated and the FDA approval route
- 02
IND submission, the 30-day wait and three clinical trial phases
- 03
New Drug Applications, Biologics License Applications and attrition
- 04
GMP, quality control, quality assurance, validation and SOPs
- 05
Advanced therapy categories and the EU default classification rules
- 06
Autologous and allogeneic products and how each is manufactured
- 07
Engineering ethics principles and historical case studies
- 08
Embryonic and induced pluripotent stem cells, consent and animal research law
Worked example · free
Count trial participants along the approval route
- 1The sponsor must wait 30 calendar days after submitting the IND. From 12 January, 19 days reach 31 January and 11 more reach 11 February, so the earliest start is 11 February 2027.
- 2Phase I checks safety using 20 to 80 healthy volunteers; Phase II looks for efficacy in 100 to 300 patients with the condition; Phase III measures benefit against current treatment in 1,000 to 3,000 patients under double-blind conditions.
- 1Smallest total = 20 + 100 + 1,000 = 1,120 participants. Largest total = 80 + 300 + 3,000 = 3,380 participants.
- 1A vaccine is a biologically derived product, so the firm files a Biologics License Application (BLA) rather than a New Drug Application.
- 1During review the FDA checks the information that will appear on the label and inspects the facility where the vaccine will be manufactured.
Key terms
- Investigational New Drug application
- The submission a sponsor makes to the FDA, backed by animal data, asking permission to begin testing a candidate in people.
- Biologics License Application
- The licence request filed for products of biological origin, for example vaccines, blood products or proteins taken from animals.
- Good Manufacturing Practice
- A body of quality regulations that manufacturers of medicines must follow so every batch is safe and consistent.
- Standard operating procedure
- Written step-by-step instructions, with scope, responsibilities and approval signatures, for a routine task.
- Tissue-engineered product
- An advanced therapy whose cells or tissues are given to regenerate, repair or replace human tissue.
Ethics and Regulation of Biotherapeutics FAQ
How many people take part in each phase of a clinical trial?
Phase I usually enrols 20 to 80 healthy volunteers to check safety. Phase II tests whether the treatment works in 100 to 300 patients who have the illness. Phase III compares the new product with existing treatment in 1,000 to 3,000 patients using double-blinded tests, so each later phase is larger, rising from tens of volunteers to thousands of patients.
What is the difference between an NDA and a BLA?
A New Drug Application is the licence request for a conventional drug. A Biologics License Application covers products made from biological sources, including vaccines, blood components, viral therapies and proteins derived from animals. For either one the FDA reviews the proposed label and inspects the manufacturing facility before approval.
Do orphan drugs skip Phase II and Phase III trials?
No. Orphan designation gives developers of medicines for rare conditions incentives, but evidence that the medicine works must still be provided. Products against biological, chemical or nuclear threats are a separate case: efficacy may come from animal studies when human efficacy trials would be unethical, while human safety data are still needed.
Why are human embryonic stem cells ethically controversial?
Deriving hESCs from a blastocyst usually destroys the embryo. In the UK the embryos are surplus ones from IVF treatment, donated with the parents' informed consent, and the Human Fertilisation and Embryology Act 1990 with its 2001 regulations controls who may derive cell lines and where. In the US, federal funding was restricted from August 2001.
How are advanced therapy medicinal products classified in the EU?
They are sorted into gene therapy, somatic cell therapy and tissue-engineered products, plus a combined class when a device is integral. Default rules settle overlaps: mixed donor and patient cells count as allogeneic, a product meeting somatic and tissue-engineered definitions is a TEP, and one meeting all three is a gene therapy product.
Exam move
Treat this chapter as a set of short, reliable recall answers plus one argued case. First, memorise the approval route as six boxes with the participant range under each trial phase, and practise writing the full names of IND, NDA and BLA without abbreviation slips. Second, learn the four ATMP classes with one named product each and the four default rules, then classify invented products until the rules feel automatic.
Third, prepare a balanced comparison of autologous and allogeneic therapies, because model answers split the marks evenly between the two sides. For ethics questions, plan each paragraph around a principle, the fact that triggers it and the law or regulator involved, and qualify strong claims such as iPSCs having no ethical issues.
Finally, do not spend revision time on health economics calculations, which the current lecture notes do not teach.